RhumbLine Advisers
CMPX icon

RhumbLine Advisers’s Compass Therapeutics CMPX Stock Holding History

RhumbLine Advisers’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$778K Buy
147,016
+12,411
+9% +$71.6K ﹤0.01% 2332
2025
Q4 		$723K Sell
134,605
-4,708
-3% -$21.7K ﹤0.01% 2420
2025
Q3 		$488K Buy
139,313
+25,826
+23% +$81.6K ﹤0.01% 2717
2025
Q2 		$295K Sell
113,487
-6,542
-5% -$13.5K ﹤0.01% 2997
2025
Q1 		$228K Sell
120,029
-9,087
-7% -$24.2K ﹤0.01% 3043
2024
Q4 		$187K Buy
129,116
+3,822
+3% +$6.35K ﹤0.01% 3229
2024
Q3 		$231K Sell
125,294
-6,495
-5% -$8.1K ﹤0.01% 3164
2024
Q2 		$132K Buy
131,789
+12,315
+10% +$18K ﹤0.01% 3425
2024
Q1 		$237K Buy
119,474
+2,942
+3% +$5.08K ﹤0.01% 3096
2023
Q4 		$182K Sell
116,532
-587
-0.5% -$1.02K ﹤0.01% 3229
2023
Q3 		$231K Buy
117,119
+4,791
+4% +$11.8K ﹤0.01% 3078
2023
Q2 		$357K Buy
+112,328
New +$353K ﹤0.01% 2896

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RhumbLine Advisers's CMPX Position: Q1 2026 in Review

RhumbLine Advisers increased its Compass Therapeutics (CMPX) stake by 9.2% in Q1 2026, buying an estimated $71.6K and bringing the position to 147,016 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

RhumbLine Advisers first reported a position in CMPX in Q2 2023 and has held it in 12 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • RhumbLine Advisers held 147,016 shares of Compass Therapeutics worth $778K as of Q1 2026.
  • RhumbLine Advisers bought 12,411 Compass Therapeutics shares in Q1 2026, an estimated $71.6K.
  • Compass Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2332 holding.
  • RhumbLine Advisers first reported a position in Compass Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.